Aandeel Galapagos AEX:GLPG.NL, BE0003818359

quote:

Mr Greenspan schreef op 9 januari 2016:

Is dit nog wat (drug tot drug interactie)
clinicaltrials.gov/ct2/show/NCT02623296

quote:

asti schreef op 10 januari 2016 15:36:

Webcast 17 dec

Jan De Kerpel - KBC Securities N.V. - Analyst

Okay. I see. If I may, a small followup question. Gilead indeed doesn't have late-stage products in inflammation, but they do have a few products in an early stage -- an antibody, if I'm not mistaken, and a Syk inhibitor. Do you see any possibilities of combination with those kind of molecules with filgotinib?

Onno van de Stolpe - Galapagos NV - CEO

That's a good question, Jan. And clearly, yes, Gilead is a combination therapy Company, as they have shown with HIV and HCV franchises. So, clearly, combination products have been discussed. And we also believe that the future of effective treatment in RA and IBD will be combination products to really lead to very high remission rates. Although filgotinib has a very good remission rate, there's always improvement possible.
So, I think, longer-term, combination products will be the way to go, and we believe that with Gilead we've got a very good partner that is keen on exploring that kind of combination program. So, we will at some point start combination products in Phase IIs.

(...)

Marc Frahm - Cowen and Company - Analyst

Okay. And then as you -- in the last question was brought up potential combination therapies. How is that contemplated in the partnership in terms of economics, and who sets the price and the relative value of filgotinib versus whatever else might be combined with it?

Bart Filius - Galapagos NV - CFO

Yes. So, the combination product -- that would be at -- Gilead's call to make decisions on further developments on those. We will also not be contributing to the cost of development of combination products.
And there is an agreement between the parties, how the value of filgotinib as part of a combination product, will be treated. It will be treated fairly, so there will be revenues for Galapagos from the filgotinib contribution to any combination product that Gilead might develop.

quote:

NielsjeB schreef op 10 januari 2016 15:53:

[...]
In zulke gevallen dus extra royalties zonder kosten! AB om het nog eens onder de aandacht te brengen. Zou LT best wel eens voor een flinke royaltyboost kunnen zorgen. Zoals bekend is Gilead inderdaad de combination-company.

quote:

asti schreef op 10 januari 2016 15:36:

Webcast 17 dec

Jan De Kerpel - KBC Securities N.V. - Analyst

Okay. I see. If I may, a small followup question. Gilead indeed doesn't have late-stage products in inflammation, but they do have a few products in an early stage -- an antibody, if I'm not mistaken, and a Syk inhibitor. Do you see any possibilities of combination with those kind of molecules with filgotinib?

Onno van de Stolpe - Galapagos NV - CEO

That's a good question, Jan. And clearly, yes, Gilead is a combination therapy Company, as they have shown with HIV and HCV franchises. So, clearly, combination products have been discussed. And we also believe that the future of effective treatment in RA and IBD will be combination products to really lead to very high remission rates. Although filgotinib has a very good remission rate, there's always improvement possible.
So, I think, longer-term, combination products will be the way to go, and we believe that with Gilead we've got a very good partner that is keen on exploring that kind of combination program. So, we will at some point start combination products in Phase IIs.

(...)

Marc Frahm - Cowen and Company - Analyst

Okay. And then as you -- in the last question was brought up potential combination therapies. How is that contemplated in the partnership in terms of economics, and who sets the price and the relative value of filgotinib versus whatever else might be combined with it?

Bart Filius - Galapagos NV - CFO

Yes. So, the combination product -- that would be at -- Gilead's call to make decisions on further developments on those. We will also not be contributing to the cost of development of combination products.
And there is an agreement between the parties, how the value of filgotinib as part of a combination product, will be treated. It will be treated fairly, so there will be revenues for Galapagos from the filgotinib contribution to any combination product that Gilead might develop.

quote:

Mr Greenspan schreef op 10 januari 2016 21:23:

[...]

Volgens mij had vd Stolpe het er bij de nieuwjaarsborrel zelfs over dat ze nog dit jaar een combi in fase 2 willen starten (er werd veel over gesproken met Gilead). Niet helemaal zeker maar ik dacht dat vd Stolpe van 70% naar 80 a 90% verbetering wilde.